Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amarin Corporation PLC (NASDAQ:AMRN)

2.23
Delayed Data
As of Aug 28
 +0.14 / +6.70%
Today’s Change
0.78
Today|||52-Week Range
3.33
+127.62%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$407.0M

Company Description

Amarin Corp. Plc is a biopharmaceutical company, which is focused on the commercialization and development of therapeutics to improve cardiovascular health. The company's product Vascepa capsules is an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The company is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol. Amarin was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Contact Information

Amarin Corp. Plc
2 Pembroke House
Dublin Dublin 00200
P:(531) 669-9020
Investor Relations:

Employees

Shareholders

Mutual fund holders4.83%
Individual stakeholders4.80%
Other institutional25.96%

Top Executives

John F. TheroPresident, Chief Executive Officer & Director
Michael J. FarrellChief Financial & Accounting Officer
Steven B. KetchumSenior VP, President-Research & Development
Joseph T. KennedySecretary, Chief Compliance Officer & Senior VP
William G. StirtanVice President-Project Management